STALLERGENES-GREER
30.7.2024 12:10:28 CEST | Business Wire | Press release
Stallergenes Greer, a leading global healthcare company specialising in allergen immunotherapy, today announced that the U.S Food and Drug Administration (FDA) has approved Palforzia® [Peanut (Arachis hypogaea) Allergen Powder-dnfp], for the treatment of toddlers (ages 1-3 years) with a confirmed diagnosis of a peanut allergy. This approval expands the January 2020 FDA approval for patients ages 4-17 years. Palforzia® is to date the first and only approved oral immunotherapy treatment (OIT) for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut.
Peanut allergy currently affects approximately 2% of the general population of Western nations1, and the prevalence of peanut allergy doubled among children between 2005 and 20152. Compared with other food allergies, peanut allergy is associated with higher rates of accidental exposure, severe reactions and potentially fatal anaphylaxis1. The difficulty in avoiding peanuts, combined with the severity of allergic reactions, shows the need for effective treatment3.
“We are delighted that Palforzia® has received regulatory approval in the U.S. for toddlers as there is a high unmet medical need for this age group and we are confident that this indication extension will alleviate the burden of peanut allergy for younger patients and their families,” says Elena Rizova, MD, PHD, Chief Medical Officer of Stallergenes Greer.
The FDA approval in toddlers is based on data from the Phase 3 POSEIDON (Peanut Oral Immunotherapy Study of Early Intervention for Desensitization) study that was published in the New England Journal of Medicine Evidence in 2023. The study evaluated the efficacy and safety of Palforzia® in peanut-allergic children aged 1 to 3 years old, meeting all its primary and secondary efficacy endpoints and demonstrating a favourable safety profile.
Stallergenes Greer acquired the rights to Palforzia® in September 2023. As part of our ongoing commitment to delivering innovative solutions in allergen immunotherapy, our focus in the U.S has been on establishing a specialised Food Allergy business unit and transitioning the product into our AIT portfolio.
ABOUT PALFORZIA®
Palforzia® is in the U.S an oral immunotherapy treatment indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut for patients. The treatment is approved for use in patients with a confirmed diagnosis of peanut allergy and in conjunction with a peanut-avoidant diet. Limitation of Use: Not indicated for the emergency treatment of allergic reactions, including anaphylaxis.
Palforzia® is approved by the U.S. Food and Drug Administration (FDA) for ages 1-17 years and for ages 4-17 years by the European Medicine Agency (EMA), by the Medicines and Healthcare products Regulatory Agency (MHRA) in the U.K., and by Swissmedic in Switzerland. Pediatric indication extension submissions are currently under review by the EMA and Swissmedic.
ABOUT POSEIDON PHASE 3 STUDY
POSEIDON (Peanut Oral Immunotherapy Study of Early Intervention for Desensitization, clinicaltrials.gov number NCT03736447) is an international, randomized (2:1), double-blind, placebo-controlled Phase 3 study that evaluated the efficacy and safety of Palforzia® in peanut-allergic children aged 1 to 3 years of age in North America and Europe.
The POSEIDON study was completed by Aimmune Therapeutics, part of Nestlé Health Science before Nestlé divested Palforzia® to Stallergenes Greer in September 2023.
Enrollment was based on several entry criteria, including a documented clinical history of peanut allergy, positive skin prick tests and/or elevated blood levels of peanut antibodies, and dose-limiting symptoms after consuming single doses of peanut protein >3 to ≤300 mg in a positive double-blind, placebo-controlled food challenge.
In POSEIDON, patients underwent a dose-escalation period of approximately 22 weeks to reach a dose of 300 mg per day of Palforzia® or placebo, then continued that dose for approximately six months. At the end of the trial, patients underwent an exit double-blind, placebo-controlled food challenge (DBPCFC).
ABOUT STALLERGENES GREER INTERNATIONAL AG
Headquartered in Baar (Switzerland), Stallergenes Greer International AG is a global healthcare company specialising in the diagnosis and treatment of respiratory, food and venom allergies through the development and commercialisation of allergen immunotherapy products and services. Stallergenes Greer International AG is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France). For more information, visit www.stallergenesgreer.com.
1 The global burden of illness of peanut allergy: A comprehensive literature review. Jay A. Lieberman, Ruchi S Gupta, Rebecca C. Knibb, Tmirah Haselkorn, Stephen Tilles, Douglas P. Mack, and Guillaume Pouessel. Online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247890/ Accessed August 31, 2023
2 Du Toit G, et al. Randomized Trial of Peanut Consumption in Infants at Risk for Peanut Allergy. N Engl J Med 2015; 372: 803-13. Accessed August 31, 2023.
3 Bock SA, Muñoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol. 2001;107:191-3. Accessed August 31, 2023.
Palforzia®: © 2023, Société des Produits Nestlé S.A. or its affiliates
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240730211334/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ViTAA Medical and The Society for Vascular Surgery Announce Strategic Partnership20.11.2026 15:00:00 CET | Press release
ViTAA Medical to Become Key SVS AI Partner, Advancing AI Education and Responsible Adoption in Vascular Care ViTAA Medical Solutions Inc. (ViTAA) today announced a strategic partnership with The Society for Vascular Surgery (SVS) to advance evidence, education, and the responsible adoption of quantitative imaging and artificial intelligence in vascular care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120954362/en/ The partnership will support evidence building, best practices, educational resources for SVS members, physicians and trainees on AI validation, interpretation, and clinical limitations. The relationship has the potential to pave the way for additional AI tools and resources for SVS members through the Society in the future. The partnership creates a framework for the organizations to lead AI-enabled research opportunities involving imaging and clinical outcomes. Mitchel Benovoy, PhD, Chief Executive Officer
Epitech Group and Horus Pharma sign a global licensing agreement to develop adelmidrol in eye health20.11.2026 14:39:00 CET | Press release
Epitech Group S.p.A., an Italian biopharmaceutical firm specializing in neuro-inflammation, and Horus Pharma, a French laboratory specializing in ophthalmology, announce a global licensing agreement for adelmidrol, a molecule belonging to the ALIAmide family, developed by Epitech Group. This agreement grants Horus Pharma exclusive rights to develop and market adelmidrol for human ophthalmology and periocular dermatology applications. It aims to explore new approaches to address unmet medical needs in eye health. A combination of complementary scientific expertise Epitech Group has been studying ALIAmides and their role in physiological regulatory mechanisms for over 30 years, building on the research of Rita Levi-Montalcini, the 1986 Nobel Prize in Medicine laureate who first identified the ALIA mechanism. Horus Pharma, for its part, contributes over 20 years of ophthalmology expertise, strong R&D capabilities, and its international presence. Against the backdrop of an aging population
Adyen Merchants Can Now Offer Klarna in AI Agent Checkout20.11.2026 14:30:00 CET | Press release
Klarna is Adyen’s first non-card, local payment method for agentic commerce Klarna (NYSE: KLAR), the everyday finance network, and Adyen (AMS: ADYEN) today announced that shoppers can now pay with Klarna when an AI agent checks out for them through Adyen Agentic. Klarna is the first payment option beyond cards available in Adyen Agentic, Adyen’s agentic commerce suite, and merchants that already offer Klarna through Adyen can switch it on with no new integration work. Today, most AI shopping agents complete purchases with a stored credit or debit card, leaving out flexible payment options that many shoppers choose at regular checkout. With Klarna now a payment method within Adyen Agentic, the agent shows shoppers the same Klarna options the merchant already offers, such as paying in full, in interest-free installments or with financing. Shoppers review and confirm every purchase before it is completed. Adyen built the integration on Klarna’s open payment handler, a published specificat
SatSure Raises Series B to Scale Its Full-Stack Earth Intelligence Platform for Global Markets20.11.2026 11:05:00 CET | Press release
India’s sovereign space-technology fund leads the first close of the ongoing INR 200 crore (c. USD 21 million) round SatSure, a global Earth intelligence company headquartered in India, today announced the first close of its ongoing INR 200 crore (c. USD 21 million) Series B round. The round is led by a INR 60 crore (c. USD 6.4 million) investment from the Antariksh Venture Capital Fund (AVCF), India’s sovereign space-technology fund, anchored by the national space regulator IN-SPACe and managed by SIDBI Venture Capital Limited. The investment marks AVCF’s first deployment into the downstream data and AI layer of India’s space economy, extending the fund beyond upstream launch and satellite hardware into commercial space-data infrastructure capable of serving global enterprise and sovereign markets. The round comprises INR 165 crore (c. USD 17.6 million) in equity, INR 25 crore (c. USD 2.7 million) in venture debt and INR 10 crore (c. USD 1.1 million) in secondary transactions, closing
Al Shera’a, DEWA’s Headquarters, Wins First Place in the YeS Honor Awards at the COP31 International Sustainable Buildings Competition20.11.2026 10:16:00 CET | Press release
In a new achievement that underscores Dubai’s pioneering position in smart and sustainable buildings, Al Shera’a, the headquarters of Dubai Electricity and Water Authority (DEWA), has won the first place in the YeS Honor Award–Sustainable Design category, in the COP31 International Sustainable Buildings Competition. The award was launched by the COP31 Presidency with the support of the Global Alliance for Buildings and Construction, hosted by the United Nations Environment Programme, during COP31 in Antalya, Türkiye. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118255551/en/ HE Saeed Mohammed Al Tayer, MD&CEO of DEWA, received the award in the presence of HE Amna bint Abdullah Al Dahak, UAE Minister of Climate Change and Environment, from HE Hasan Suver, Deputy Minister of Environment, Urbanisation and Climate Change of the Republic of Türkiye, representing the COP31 Presidency. The competition attracted more than 1,000
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
